p-methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro

Journal of Neurochemistry

Volumn 82, Issue 6, 2002, Pages 1435-1443

  Gobbi, M ^a   Moia, M ^a   Pirona, L ^a   Ceglia, I ^a   Reyes Parada, M ^b   Scorza, C ^c   Mennini, T ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^c INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

Author keywords

1 (m chlorophenyl)piperazine; 3,4 methylenedioxymethamphetamine; 5 HT release; p chloroamphetamine; p methylthioamphetamine; Synaptosomes

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHYLTHIOAMPHETAMINE; AMPHETAMINE DERIVATIVE; CHLORAMPHETAMINE; CITALOPRAM; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; BRAIN SYNAPTOSOME; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; MALE; MICRODIALYSIS; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SEROTONIN RELEASE; SYNAPTIC MEMBRANE; SYNAPTOSOME;

AMPHETAMINES; ANIMALS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CARRIER PROTEINS; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE ENDINGS; NERVE TISSUE PROTEINS; P-CHLOROAMPHETAMINE; PIPERAZINES; RATS; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOSOMES; TRITIUM;

ANIMALIA;

EID: 0036734870     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01073.x     Document Type: Article

References (45)

1. Baumann M. H., Mash D. C. and Staley J. K. (1995) The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport 6, 2150-2152.
2. Baumann M. H., Rutter J. J. and Auerbach S. B. (1993) Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 32, 1381-1386.
3. Baumann M. H., Ayestas M. A., Dersch C. M. and Rothman R. B. (2001) 1-(m-chlorophenyl) piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24, 492-501.
4. Colado M. I., O'Shea E., Granados R., Murray T. K. and Green A. R. (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121, 889-900.
5. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br. J. Pharmacol. 121, 1735-1743.
6. Eriksson E., Engberg G., Bing O. and Nissbrandt H. (1999) Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20, 287-296.
7. Eshleman A. J., Carmolli M., Cumbay M., Martens C. R., Neve K. A. and Janowsky A. (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289, 877-885.
8. Fuller R. W., Snoddy H. D., Mason N. R. and Owen J. E. (1981) Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 20, 155-162.
9. Giusti P., Buriani A., Cima L. and Lipartiti M. (1997) Effect of acute and chronic tramadol on [3H]-5-HT uptake in rat cortical synaptosomes. Br. J. Pharmacol. 122, 302-306.
10. Gobbi M. and Mennini T. (1999) Release studies with rat brain cortical synaptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blocker and not a 5-hydroxytryptamine releaser. Eur. J. Pharmacol. 370, 23-26.
11. Gobbi M., Frittoli E., Mennini T. and Garattini S. (1992) Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. Naunyn-Schmiedebergs Arch. Pharmacol. 345, 1-6.
12. Gobbi M., Mennini T. and Garattini S. (1997) Mechanism of neurotransmitter release induced by amphetamine derivatives: pharmacological and toxicological aspects. Current Topics Pharmacol. 3, 217-227.
13. Gobbi M., Parazzoli A. and Mennini T. (1998) In vitro studies on the mechanism by which (+)-norfenfluramine induces serotonin and dopamine release from the vesicular storage pool. Naunyn-Schmiedebergs Arch. Pharmacol. 358, 323-327.
14. Gobbi M., Dalla Valle F., Ciapparelli C., Diomede L., Morazzoni P., Verotta L., Caccia S., Cervo L. and Mennini T. (1999) Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedebergs Arch. Pharmacol. 360, 262-269.
15. Gray E. G. and Whittaker V. P. (1962) The isolation of nerve endings from brain: an electron-microscope study of cell fragments derived by homogenization and centrifugation. J. Anat. 96, 79-87.
16. Green A. R., Cross A. J. and Goodwin G. M. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology 119, 247-260.
17. Gudelsky G. A. (1996) Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J. Neural Transm. 103, 1397-1404.
18. Huang X., Marona-Lewicka D. and Nichols D. E. (1992) p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J. Pharmacol. 229, 31-38.
19. Invemizzi R., Fracasso C., Caccia S., Di Clemente A., Garattini S. and Samanin R. (1989) Effect of 1-cysteine on the long-term depletion of brain indoles caused by p-chloroamphetamine and d-fenfluramine in rats. Relation to brain drug concentrations. Eur. J. Pharmacol. 163, 77-83.
20. Invemizzi R., Belli S. and Samanin R. (1992) Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584, 322-324.
21. Johnson M. P., Conarty P. F. and Nichols D. E. (1991) [3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol. 200, 9-16.
22. Johnson M. P. and Nichols D. E. (1991) Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology 30, 819-822.
23. Jones S. R., Gainetdinov R. R., Wightman R. M. and Caron M. G. (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 1979-1986.
24. Mamounas L. A. and Molliver M. E. (1988) Evidence for dual serotonergic projections to neocortex: axons from the dorsal and medial raphe nuclei are differentially vulnerable to the neurotoxin p-chloroamphetamine (PCA). Exp. Neurol. 102, 23-36.
25. Mennini T., Borroni E., Samanin R. and Garattini S. (1981) Evidence of the existence of two different intraneuronal pools from which pharmacological agents can release serotonin. Neurochem. Int. 3, 289-294.
26. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotoxic Coordinates. Academic Press, Sydney.
27. Pettibone D. J. and Williams M. (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem. Pharmacol. 33, 1531-1535.
28. Raiteri M., Angelini F. and Levi G. (1974) A simple apparatus for studying the release of neurotransmitters from synaptosomes. Eur. J. Pharmacol. 25, 411-414.
29. Reimann W. and Schneider F. (1998) Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine. Eur. J. Pharmacol. 349, 199-203.
30. Rudnick G. and Wall S. C. (1992a) The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 89, 1817-1821.
31. Rudnick G. and Wall S. C. (1992b) p-Chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry 31, 6710-6718.
32. Rudnick G. and Wall S. C. (1993) Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol. Pharmacol. 43, 271-276.
33. Sanders-Bush E., Bushing J. A. and Sulser F. (1975) Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms. J. Pharmacol. Exp. Ther. 192, 33-41.
34. Schmidt C. J. (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240, 1-7.
35. Schmidt C. J., Black C. K. and Taylor V. L. (1990) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur. J. Pharmacol. 181, 59-70.
36. Scholze P., Zwach J., Kattinger A., Pifl C., Singer E. A. and Sitte H. H. (2000) Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J. Pharmacol. Exp. Ther. 293, 870-878.
37. Schuldiner S., Steiner-Mordoch S., Yelin R., Wall S. C. and Rudnick G. (1993) Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44, 1227-1231.
38. Scorza C., Silveira R., Nichols D. E. and Reyes-Parada M. (1999) Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Neuropharmacology 38, 1055-1061.
39. Shankaran M., Yamamoto B. K. and Gudelsky G. A. (1999) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 385, 103-110.
40. Sitte H. H., Scholze P., Schloss P., Pifl C. and Singer E. A. (2000) Characterization of carrier-mediated efflux in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study. J. Neurochem. 74, 1317-1324.
41. Sprague J. E. and Nichols D. E. (1995) The monoamine oxidase-B inhibitor 1-Deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667-671.
42. Sprague J. E., Everman S. L. and Nichols D. E. (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19, 427-441.
43. Stone D. M., Johnson M., Hanson G. R. and Gibb J. W. (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247, 79-87.
44. Wolf W. A. and Kuhn D. M. (1991) The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem. Int. 19, 39-44.
45. Xia X. G., Schmidt N., Teismann P., Ferger B. and Schulz J. B. (2001) Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. J. Neurochem. 79, 63-70.